Lapatinib Recruiting Phase 2 Trials for Breast Diseases / HER2 Positive Breast Carcinoma / Neoplasms, Breast / Capecitabine / Her2-Positive Breast Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03500380A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
NCT03273595Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer